Skip to main content

Advertisement

Table 1 Overview of radionuclides and corresponding ligands used in this study

From: 44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617

Nuclide Half-life Radiation energy Ligand Chelator Application Refs.
44Sc 4.04 h + av = 632 keV Eγ = 1157 keV* PSMA-617 DOTA PET (β+-radiation) Evaluated in this study
177Lu 6.65 days av = 134 keV Eγ = 113 keV, 208 keV PSMA-617 DOTA Therapy/SPECT (β/γ-radiation) [22, 3739]
68Ga 68 min + av = 830 keV Eγ = 1077 keV** PSMA-617 PSMA-11 DOTA HBED-CC PET (β+-radiation) [21] [17, 18, 40]
  1. *I = 99.9%; **I = 3.2%